306 related articles for article (PubMed ID: 22383795)
1. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
Leonard JP; LaCasce AS; Smith MR; Noy A; Chirieac LR; Rodig SJ; Yu JQ; Vallabhajosula S; Schoder H; English P; Neuberg DS; Martin P; Millenson MM; Ely SA; Courtney R; Shaik N; Wilner KD; Randolph S; Van den Abbeele AD; Chen-Kiang SY; Yap JT; Shapiro GI
Blood; 2012 May; 119(20):4597-607. PubMed ID: 22383795
[TBL] [Abstract][Full Text] [Related]
2. CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment.
DeMichele A; Clark AS; Tan KS; Heitjan DF; Gramlich K; Gallagher M; Lal P; Feldman M; Zhang P; Colameco C; Lewis D; Langer M; Goodman N; Domchek S; Gogineni K; Rosen M; Fox K; O'Dwyer P
Clin Cancer Res; 2015 Mar; 21(5):995-1001. PubMed ID: 25501126
[TBL] [Abstract][Full Text] [Related]
3. Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development.
Clark AS; Karasic TB; DeMichele A; Vaughn DJ; O'Hara M; Perini R; Zhang P; Lal P; Feldman M; Gallagher M; O'Dwyer PJ
JAMA Oncol; 2016 Feb; 2(2):253-60. PubMed ID: 26633733
[TBL] [Abstract][Full Text] [Related]
4. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
5. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
Dickson MA; Tap WD; Keohan ML; D'Angelo SP; Gounder MM; Antonescu CR; Landa J; Qin LX; Rathbone DD; Condy MM; Ustoyev Y; Crago AM; Singer S; Schwartz GK
J Clin Oncol; 2013 Jun; 31(16):2024-8. PubMed ID: 23569312
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
8. Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.
Marzec M; Kasprzycka M; Lai R; Gladden AB; Wlodarski P; Tomczak E; Nowell P; Deprimo SE; Sadis S; Eck S; Schuster SJ; Diehl JA; Wasik MA
Blood; 2006 Sep; 108(5):1744-50. PubMed ID: 16690963
[TBL] [Abstract][Full Text] [Related]
9. Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.
Wang K; Huang X; Di Liberto M; Chen-Kiang S
Hematol Oncol Clin North Am; 2020 Oct; 34(5):809-823. PubMed ID: 32861279
[TBL] [Abstract][Full Text] [Related]
10. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
Dickson MA; Schwartz GK; Keohan ML; D'Angelo SP; Gounder MM; Chi P; Antonescu CR; Landa J; Qin LX; Crago AM; Singer S; Koff A; Tap WD
JAMA Oncol; 2016 Jul; 2(7):937-40. PubMed ID: 27124835
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients.
Tamura K; Mukai H; Naito Y; Yonemori K; Kodaira M; Tanabe Y; Yamamoto N; Osera S; Sasaki M; Mori Y; Hashigaki S; Nagasawa T; Umeyama Y; Yoshino T
Cancer Sci; 2016 Jun; 107(6):755-63. PubMed ID: 26991823
[TBL] [Abstract][Full Text] [Related]
12. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
[TBL] [Abstract][Full Text] [Related]
13. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
Paternot S; Colleoni B; Bisteau X; Roger PP
Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase pathways as targets for women's cancer treatment.
Konecny GE
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):42-8. PubMed ID: 26642065
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC-042).
Van Mater D; Gururangan S; Becher O; Campagne O; Leary S; Phillips JJ; Huang J; Lin T; Poussaint TY; Goldman S; Baxter P; Dhall G; Robinson G; DeWire-Schottmiller M; Hwang EI; Stewart CF; Onar-Thomas A; Dunkel IJ; Fouladi M
Pediatr Blood Cancer; 2021 Apr; 68(4):e28879. PubMed ID: 33405376
[TBL] [Abstract][Full Text] [Related]
16. CDK4-6 inhibitors in breast cancer: current status and future development.
Choo JR; Lee SC
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
18. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
[TBL] [Abstract][Full Text] [Related]
19. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of CDK4/Rb and PI3K/AKT/mTOR pathways by ON123300 induces synthetic lethality in mantle cell lymphomas.
Divakar SK; Ramana Reddy MV; Cosenza SC; Baker SJ; Perumal D; Antonelli AC; Brody J; Akula B; Parekh S; Reddy EP
Leukemia; 2016 Jan; 30(1):86-93. PubMed ID: 26174628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
